Epizyme Reports Fourth Quarter and Full Year 2017 Operating Results and 2018 Milestones
First Tazemetostat NDA Submission for Epithelioid Sarcoma Targeted for Fourth Quarter of 2018; Second Tazemetostat NDA Submission for Follicular Lymphoma Targeted for 2019 Multiple Phase 2 Study Data Readouts Planned in 2018 Conference Call to be Held …